Skip to main content

Research Repository

Advanced Search

Browse


The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ (2021)
Journal Article
Al-Kawaz, A., Miligy, I. M., Toss, M. S., Mohammed, O. J., Green, A. R., Madhusudan, S., & Rakha, E. A. (2021). The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. Breast Cancer Research and Treatment, https://doi.org/10.1007/s10549-021-06271-y

Background Impaired DNA repair mechanism is one of the cancer hallmarks. Flap Endonuclease 1 (FEN1) is essential for genomic integrity. FEN1 has key roles during base excision repair (BER) and replication. We hypothesised a role for FEN1 in breast c... Read More about The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer (2021)
Journal Article
Alfarsi, L. H., Ansari, R. E., Craze, M. L., Mohammed, O. J., Masisi, B. K., Ellis, I. O., …Green, A. R. (in press). SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment,

Purpose: Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The... Read More about SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer.

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray (2020)
Journal Article
Parks, R. M., Albanghali, M. A., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2021). Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray. Breast Cancer Research and Treatment, 185(3), 647–655. https://doi.org/10.1007/s10549-020-06023-4

© 2020, The Author(s). Purpose: Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor (HER)-2. This study uses a uniq... Read More about Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray.

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer (2020)
Journal Article
Elsharawy, K. A., Althobiti, M., Mohammed, O. J., Aljohani, A. I., Toss, M. S., Green, A. R., & Rakha, E. (2021). Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 185(3), 615-627. https://doi.org/10.1007/s10549-020-05999-3

Purpose Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC). Methods... Read More about Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.

The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer (2020)
Journal Article
Kariri, Y., Alsaleem, M., Joseph, C., Alsaeed, S., Aljohani, A., Shiino, S., …Rakha, E. A. (2021). The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research and Treatment, 185(2), 293–305. https://doi.org/10.1007/s10549-020-05955-1

Background Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15... Read More about The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer.

The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer (2020)
Journal Article
Elsharawy, K. A., Mohammed, O. J., Aleskandarany, M. A., Hyder, A., El-Gammal, H. L., -Dobara, A., …Rakha, E. A. (2020). The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer. British Journal of Cancer, 123, 1543–1552. https://doi.org/10.1038/s41416-020-01045-7

Background Hypertrophy of the nucleolus is a distinctive cytological feature of malignant cells and corresponds to aggressive behaviour. This study aimed to identify the key gene associated with nucleolar prominence (NP) in breast cancer (BC) and... Read More about The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets (2020)
Journal Article
Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E., Fujii, T., …Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 22, https://doi.org/10.1186/s13058-020-01324-4

© 2020 The Author(s). Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable... Read More about Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ (2020)
Journal Article
Miligy, I. M., Toss, M. S., Shiino, S., Oni, G., Syed, B. M., Khout, H., …Rakha, E. A. (2020). The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 123, 1513–1520. https://doi.org/10.1038/s41416-020-1023-3

Background: Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to endocrine therapy (ET) and provides prognostic value. In this study, we investigated the value of ER expression in ductal carcinoma in situ (DCIS) in terms of out... Read More about The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.

Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome (2020)
Journal Article
Parks, R. M., Albanghali, M., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2020). Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome. Cancers, 12(8), https://doi.org/10.3390/cancers12082067

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The majority of biological profiling studies use surgical excision (SE) samples, excluding patients receiving nonsurgical and neoadjuvant therapy. We propose using core needle biopsy (CNB) for... Read More about Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome.

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis (2020)
Journal Article
Siersbaek, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., …Carroll, J. S. (2020). IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. Cancer Cell, 38(3), 412-423.e9. https://doi.org/10.1016/j.ccell.2020.06.007

The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives me... Read More about IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype (2020)
Journal Article
Kariri, Y. A., Aleskandarany, M. A., Joseph, C., Toss, M. S., Kurozumi, S., Mohammed, O. J., …Rakha, E. A. (2020). Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology, 87, 218–231. https://doi.org/10.1159/000508337

Lymphovascular invasion (LVI) is associated with poor outcome in breast cancer (BC); however, its underlying mechanisms remain ill-defined. LVI in BC develops through complex molecular pathways involving not only the interplay with the surrounding mi... Read More about Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype.

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer (2020)
Journal Article
Abdel-Fatah, T. M., Ball, G. R., Thangavelu, P. U., Reid, L. E., Reed, A. E. M., Saunus, J. M., …Chan, S. Y. (2020). Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer. JAMA Network Open, 3(7), https://doi.org/10.1001/jamanetworkopen.2020.9486

Importance There is no proven test that can guide the optimal treatment, either endocrine therapy or chemotherapy, for estrogen receptor–positive breast cancer. Objective To investigate the associations of sperm-associated antigen 5 (SPAG5) tran... Read More about Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer.

Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy (2020)
Journal Article
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020). Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 8, https://doi.org/10.3389/fcell.2020.00402

Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines, as proteins of the immune system, are able to modulate the host immune response toward cancer cell, as well as directly induce tumor cell death. Since a low d... Read More about Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy.

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival (2020)
Journal Article
Joseph, C., Alsaleem, M., Orah, N., Narasimha, P. L., Miligy, I. M., Kurozumi, S., …Rakha, E. A. (2020). Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 182, 267–282. https://doi.org/10.1007/s10549-020-05670-x

Purpose: MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of... Read More about Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer (2020)
Journal Article
Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), https://doi.org/10.1186/s12885-020-06939-6

Background PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important pro... Read More about PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

A novel prognostic two-gene signature for triple negative breast cancer (2020)
Journal Article
Alsaleem, M. A., Ball, G., Toss, M. S., Raafat, S., Aleskandarany, M., Joseph, C., …Rakha, E. (2020). A novel prognostic two-gene signature for triple negative breast cancer. Modern Pathology, 33, 2208–2220. https://doi.org/10.1038/s41379-020-0563-7

The absence of a robust risk stratification tool for triple negative breast cancer (TNBC) underlies imprecise and non-selective treatment of these patients with cytotoxic chemotherapy. This study aimed to interrogate transcriptomes of TNBC resected s... Read More about A novel prognostic two-gene signature for triple negative breast cancer.

The prognostic significance of ALDH1A1 expression in early invasive breast cancer (2020)
Journal Article
Althobiti, M., El Ansari, R., Aleskandarany, M., Joseph, C., Toss, M. S., Green, A. R., & Rakha, E. A. (2020). The prognostic significance of ALDH1A1 expression in early invasive breast cancer. Histopathology, 77(3), 437-448. https://doi.org/10.1111/his.14129

Aims: Aldehyde dehydrogenase family 1 member A1 (ALDH1A1)is reportedly a key ALDH isozyme linked to the cancer stem cells (CSC) of many solid tumours, where it is involved in self-renewal, differentiation and self-protection. In this study, the progn... Read More about The prognostic significance of ALDH1A1 expression in early invasive breast cancer.

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer (2020)
Journal Article
Aljohani, A. I., Joseph, C., Kurozumi, S., Mohammed, O. J., Miligy, I. M., Green, A. R., & Rakha, E. (2020). Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment, 181(3), 541-551. https://doi.org/10.1007/s10549-020-05646-x

Background: Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identifying factors associated with the progression of early stage BC can help understand the risk of metastasis and guide treatment dec... Read More about Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.